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Previewspromotion of angiogenesis and myelomo-
nocytic cell recruitment. Macrophages
directly enhance tumorigenicity in an
FcgR-dependent fashion. Interestingly,
here the culprit of tumor promotion was
on mature TAMs rather than on immature
elements in the myelomonocytic pathway
such as MDSC. Tumor-promoting TAMs
have a M2-like transcriptional profile. B
cell-instructed innate cells are a source of
IL-1, which activates the proinflammatory
properties of CAF (Erez et al., 2010).
The TAM profile reported by Andreu
et al. and previous profiles (Mantovani
et al., 2008) include T cell-attracting anti-
angiogenic chemokines (CXCL10 and
CXCL11). This finding emphasizes the
yin-yang dual potential of the macro-
phage-tumor cell interplay (Allavena
et al., 2008; Mantovani et al., 2008; Os-
trand-Rosenberg, 2008).
These observations raise important
general issues. B cells are a valuable
target in the therapy of autoimmune disor-
ders. Therefore, the definition of a B cell/
antibody/FcgR/macrophage pathway in
cancer-promoting inflammation identifies
potential targets for therapeutic interven-
tion. Similarly, IL-1-blocking strategies
are available or being developed for112 Cancer Cell 17, February 17, 2010 ª2010inflammatory disorders, and in both here
and elsewhere (Dinarello, 2009), IL-1 is
emerging as a key player in CRI.
Myelomonocytic cells are part of a
common pathway of inflammation-medi-
ated cancer promotion (Allavena et al.,
2008; Mantovani et al., 2008; Pollard,
2004). However, the subsets involved
(from classic mature macrophages or
neutrophils to immature myelomonocytic
cells) differ considerably in different
settings (e.g., Andreuet al., 2010;DeNardo
et al., 2009; andFridlenderet al., 2009). In a
mousemodel of metastatic breast cancer,
DeNardo and colleagues (DeNardo et al.,
2009) reported thatmacrophageM2polar-
ization and tumor promotion is driven by
T cell-produced IL-4. Thus, not only can
the subsets be different but so can the
orchestrating signals in different tumors
(Figure 1). Therefore, careful dissection of
the players, conductors and themes in
different human cancers will be required
for the clinical exploitation of our under-
standing of CRI at the bedside.REFERENCES
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Identifying transcriptional program(s) deregulated by oncoproteins is key to understanding the molecular
basis of the disease. In this issue of Cancer Cell, two studies by Martens et al. and Wang et al. provide global
blueprints for transcriptional targets and epigenetic modifications mediated by PML-RARa in acute promye-
locytic leukemia.Acute promyelocytic leukemia (APL) is
characterized by the expression of RARa
fusions and unique sensitivity to all-transretinoic acid (ATRA) treatment. As a result,
it has been the paradigm for studying dif-
ferentiation therapies and more recentlyfor epigenetic therapies. In the past de-
cades, a tremendous amount of effort
has been made to identify the aberrant
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Figure 1. Transcriptional and Epigenetic Paradigms of PML-RARa
Function
As shown in the upper panel, in the absence of ligand, PML-RARa binds to
over 3000 binding sites in vivo as complexes with interacting DNA binding
factors (DBF), such as RXR and/or PU.1, probably depending on the configu-
ration of individual sites. The majority of these sites do not correspond to
canonical RAREs. As shown in the lower panel, PML-RARa/DBF complexes
associate with multicomponent corepressor complexes including HDACs,
resulting in a low level of histone acetylation. In the presence of ATRA, core-
pressor complexes dissociate from PML-RARa/DBF, resulting in increased
histone acetylation. Although a few PR target sites show decreased H3K27
trimethylation and DNA methylation, probably as a result of PRC and Dnmt
recruitments, Martens et al. report that themajority of the sites do not undergo
such changes. The role of the few modulated sites in the pathological and
pharmacological response of the disease remains to be established. Dissoci-
ation of corepressor complexes allows access of coactivators and degrada-
tion of the PML-RARa protein. All together, this results in transcription
derepression. Illustration by Pui Yi Tse.
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Previewstranscriptional targets and
activities that account for
the leukemogenic functions
of RARa fusions. Although
some important targets and
principles have been estab-
lished from various in vitro
studies or targeted analyses
of a small number of genomic
loci, the majority of the in vivo
direct downstream targets of,
and the global epigenetic
modulation by, RARa fusions
remain largely unknown.
Using state-of-the-art ChIP-
sencing and ChIP-on-chip
technologies, two recent
studies by Martens et al.
(2010) and Wang et al. (2010)
have shed light on this issue
(Figure 1).
Co-occupancy of
Atypical RARE Binding
Sites by PML-RARa/RXR
Complexes
Martens et al. have discov-
ered over 2700 high confi-
dence PML-RARa in vivo
binding sites in NB4 cells, of
which 600 overlapped among
three different cellular APL
systems including primary
APL blasts. In contrast to
wild-type RARa binding
targets, of which 90% con-
tained canonical DR1-5
(direct repeats of the hexame-
ric recognition motif spaced
by 1 to 5 bp) retinoic acid
response elements (RAREs),
only 50% of PML-RARa
binding sites contained such
canonical RAREs, whereas
over 30% contained atypical
motifs. An independent study
by Wang et al. also investi-Histone Acgated this issue using zinc-inducible
PML-RARa expression in U937 cells.
Among 3000 identified putative PML-
RARa binding sites, they found only
a very low frequency (13%) of canonical
RAREs, most of these sites instead con-
tained atypical motifs with one or more
RARE half-sites (RAREh) variably spaced
in different orientations. Both studies re-
vealed that RXR coexists with PML-
RARa in most of the ChIPed regions.
RXR also exhibited very similar bindingcharacteristics as PML-RARa both pre-
and post-ATRA treatment (Martens
et al., 2010). Together, these results
provide the first global in vivo evidence
both consolidating and extending the
hypothesis that DNA binding targets by
homo-oligomeric PML-RARa fusion
protein are significantly different from
those of wild-type RARa (Perez et al.,
1993). They also reinforce the idea of
RXR as an essential component for APL
pathogenesis (Zeisig et al., 2007; ZhuCancer Cell 17, February 17et al., 2007), although the
actual functions of RXR in
the complexes still need to
be determined.
PU.1-Guided PML-RARa
Binding Suppresses PU.1
Functions
Bioinformatics analysis by
Wang et al. revealed that the
majority of the PML-RARa
binding sites contained at
least one RAREh together
with consensus binding sites
for specific transcription
factors including PU.1, ETS,
and AP-1, suggesting that
PML-RARa collaborates with
other factors for DNA binding.
Among them, the PU.1 motif
is by far the most common
neighbor of RAREh. Although
it was previously observed
that PU.1 is upregulated in
APL during ATRA treatment
and that forced expression of
PU.1 released the differentia-
tion block (Mueller et al.,
2006), the underlying mecha-
nisms are not completely
understood. In this study,
Wang and colleagues show
that PU.1 interacts with
PML-RARa and that its DNA
binding is required for
PML-RARa binding and
suppression of PU.1/RAREh
promoters. The study
provides a potential mecha-
nism for the reported function
of PU.1 as a myeloid differen-
tiation factor in APL and
unravels a previously unrec-
ognized role of cooperating
transcription factors in DNA
targeting of RARa fusions.
etylation Rather Than
H3K27 Methylation Associates
with ATRA Response in APL
A key question of APL pathogenesis is
how oncogenic RARa fusions (de)regulate
gene programs. Although they can recruit
different epigenetic modifiers including
histone deacetylases (HDACs) (Grignani
et al., 1998; Lin et al., 1998), polycomb
repressive complexes (PRCs) (Villa et al.,
2007), and DNA methyltransferases
(Di Croce et al., 2002), it is not clear which, 2010 ª2010 Elsevier Inc. 113
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Previews(combination) mediates the oncogenic
function(s) of RARa fusions. To gain
insights into this issue, Martens et al.
performed ChIP sequencing against
a number of histone modifications and
DNA methylation. They discovered that
histone acetylation was the only in-
vestigated mark associated with 80% of
PML-RARa in vivo binding sites and
changed dynamically upon ATRA treat-
ment. Remarkably, H3K27 trimethylation
and DNA methylation were very low and
ATRA did not induce any significant
changes in the vast majority (99%) of the
PML-RARa binding sites. Although
histone acetylation concurred with >500
PML-RARa/RXR binding sites, only 15
PML-RARa/RXR binding sites showed
differential H3K27 trimethylation or DNA
methylation. Moreover, H3 acetylation
but not H3K27 trimethylation or DNA
methylation showed strong correlation
with RNA polymerase II occupancy near
PML-RARa/RXR binding sites. Together,
these analyses provide genome-wide
evidence suggesting that histone deace-
tylation rather than H3K27 or DNAmethyl-
ation is responsible for the major
transcription repressive activity of the
onco-fusion protein and endorses the
use of HDAC inhibitors and RXR agonist
for APL.
What Have We Learnt about the
Oncogenic Function of PML-RARa?
Although the formation of PML-RARa on
its own is not sufficient to induce APL,
which requires additional (epi)genetic
event(s) toprogress fromamyeloprolifera-
tive disease to full leukemia, recent work
shows that eradicating PML-RARa is
apparently sufficient to cure the disease
by targeting the fusion protein in the
leukemia-initiating cells (LICs) (Nasr
et al., 2008). The fact that bulk leukemia
cells and LICs express PML-RARa raises
the question of whether the PML-RARa
program shown in the study by Martens
et al. is the same as that in LICs. Another
key question that remains open even after
the elegant global studies is whether it
is indeed the aberrant gene interaction
pattern of PML-RARa or nongenomic
function(s) of PML-RARa, such as interac-114 Cancer Cell 17, February 17, 2010 ª2010tion with p53, that is crucial for leukemo-
genesis.
So Much Data, So Little Time. What
To Do Now and Where To Go Next?
The two studies exemplify the unmatched
opportunity originating from the recent
explosion of array and sequencing tech-
nologies for discovery of novel chromatin
binding/regulating factors and epigenetic
marks. However, this new (epi)genomic
era also poses novel challenges and risks.
There is the technical aspect of how to
analyze millions of DNA sequences/
binding signals to distinguish ‘‘true’’
ones from noise. Too little noise indicates
lack of sequencing depth, whereas too
much noise can mask proper peak detec-
tion. Albeit continuously optimized, virtu-
ally all peak calling programs have limita-
tions. This is particularly important for
weak binding sites, which may well be
the functionally important ones we are
looking for. Given that antibodies are key
tools, quality criteria for ChIP-seq
compatible antibodies are required.
Also, the issue of epitope masking
deserves attention at global scale. The
research community will soon need to
come up with a set of standards to guar-
antee that high-quality data are generated
and accessible to wide scientific commu-
nities. While these genomic technologies
when applied appropriately will swiftly
provide us with a huge database of poten-
tially novel targets andmolecular changes
in cancer cells, it is absolutely essential to
critically investigate at the onset what new
functional insights these data will provide
and then to identify and validate key
candidate pathways in biologically rele-
vant models related to the (patho)physio-
logical phenomenon studied. Unfortu-
nately, this ultimate functional validation
remains the time-limiting step and
the bottleneck for most of the current
efforts in identifying critical cancer genes
and their associated pathways/targets.
Nevertheless, these new technologies
enabling global assessment of molecular
changes have given an unprecedented
opportunity to interrogate entire cancer
genomes and epigenomes. Not only will
this provide unique insights into theElsevier Inc.underlying transformation mechanisms
but also facilitate future drug develop-
ment, particularly for targeting epigenetic
enzymes that are key for transformation
functions of oncogenic transcription fac-
tors, which themselves are otherwise
intractable targets of small molecule
inhibitors.
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